Novo Nordisk Announces Phase 3 REDEFINE 1 Results for CagriSema in Obesity

Novo Nordisk today announced results from the Phase 3 REDEFINE 1 trial evaluating CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) in adults with obesity or overweight with weight-related comorbidities. The trial demonstrated a mean weight reduction of 22.7% from baseline at 68 weeks compared to 8.1% for placebo. CagriSema combines a long-acting amylin analogue (cagrilintide) with a GLP-1 receptor agonist (semaglutide) to provide complementary mechanisms of weight reduction. These results position CagriSema as a potential best-in-class obesity treatment. Novo Nordisk plans to submit regulatory applications for CagriSema.